Search OSUR
ORASURE TECHNOLOGIES INC
Nasdaq · CIK 1116463
Last close3.97
Daily change+0.09 (2.32%)
10 Years gain-50.56%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
OSUR · STANDARD
SIC 3841 · Surgical & Medical Instruments & Apparatus · Fiscal year end 1231
Fundamental
34.4Momentum
0.0Acceleration
8.8Confidence
89.0Annual Revenue18
Quarterly Revenue66
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth0.0 / 25
Quality9.6 / 25
Capital Efficiency0.7 / 20
Balance Sheet15.0 / 15
Shareholder Economics9.0 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 6.2898%.
Warnings
Receivables anomaly · MEDIUMAccounts receivable growth is materially above revenue growth.
Operating margin compression · MEDIUMOperating margin compressed by 25.6057 percentage points.
ROIC declining · MEDIUMROIC declined by 5.6213 percentage points.
Key Metrics
Revenue Growth TTM-34.45%OK
Revenue CAGR 3Y-33.29%OK
Gross Margin42.82%OK
Operating Margin-44.44%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-14.83%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-6.29%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $115.02M | $48.20M | -$71.97M | -$49.02M | -$53.22M | 41.9% | -62.57% | -46.27% | -40.02% | 73.49M |
| 2025 FY Dec 31, 2024 | $185.83M | $79.39M | -$28.25M | $27.37M | $23.58M | 42.72% | -15.2% | 12.69% | -15.78% | 74.43M |
| 2025 FY Dec 31, 2023 | $405.47M | $171.65M | $32.68M | $141.58M | $135.78M | 42.33% | 8.06% | 33.49% | 15.83% | 74.39M |
| 2024 FY Dec 31, 2022 | $387.48M | $148.44M | -$22.16M | -$47.20M | -$53.98M | 38.31% | -5.72% | -13.93% | -7.28% | 72.51M |
| 2023 FY Dec 31, 2021 | $233.67M | $117.60M | -$10.16M | -$35.38M | -$57.28M | 50.33% | -4.35% | -24.51% | -3.85% | 71.98M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $116.89M | sum latest 4 fiscal quarters Revenue | OK | 0001116463-26-000052, 0001116463-25-000054 |
| Revenue Growth TTM | -34.45% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001116463-26-000052, 0001116463-25-000054 |
| Revenue CAGR 3Y | -33.29% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001116463-26-000016 |
| Revenue CAGR 5Y | -7.7% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001116463-26-000016 |
| Gross Profit CAGR 3Y | -31.27% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001116463-26-000016 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001116463-26-000052, 0001116463-25-000054 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 42.82% | Gross Profit / Revenue | OK | 0001116463-26-000052, 0001116463-25-000054 |
| Operating Margin | -44.44% | Operating Income / Revenue | OK | 0001116463-26-000052, 0001116463-25-000054 |
| ROIC | -14.83% | NOPAT / Average Invested Capital | OK | 0001116463-26-000052, 0001116463-25-000054 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001116463-26-000052 |
| Current Ratio | 8.88x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $1.67 | Revenue / Diluted Shares | OK | 0001116463-26-000052, 0001116463-25-000054 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |